



Novel Antibacterial, Antibiofilm and Anti-virulence Candidates

Guest Editors:

Dr. Wael Hegazy

Dr. Amr S. Abu Lila

Dr. Tarek S. Ibrahim

Deadline for manuscript
submissions:

closed (30 November 2023)

Message from the Guest Editors

The growing microbial resistance to antibiotics is an increasingly challenging issue that global health faces. The dwindling discovery of new antibiotics worsens the situation and mandates new approaches and strategies to conquer microbial resistance. Bacteria recruit diverse virulence factors and employ several systems to control the regulation of these virulence arsenals. Among the most resistant microbial phenotypes, bacterial biofilms constitute a huge obstacle against efficient antibiotic treatments. Targeting bacterial virulence and diminishing biofilms greatly attenuates bacteria and eases their eradication through antibiotics. Targeting virulence can be achieved by targeting virulence-controlling systems. Among the most involved virulence-controlling systems, quorum sensing (QS) plays a crucial role in orchestrating the production of bacterial virulence factors and biofilms. Moreover, several approaches have been suggested to eradicate bacterial biofilms and inhibit bacterial virulence. This issue focuses on the discovery of new antibacterial and antibiofilm candidates to serve as adjuvants to antibiotics in the treatment of aggressive infections.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)